Cholinergic Agonists and Antagonists Flashcards
Steps in cholinergic transmission
ACh synthesis
ACh storage
ACh release
ACh destruction
Steps in Adrenergic Transmission
Synthesis
Storage
Release
Reuptake (destruction)
Organs and mAChR Receptors
In most organs, M3 is predominant (or receptor abundance is equal)
M2 predominant in the heart
Smooth muscle – M3, M2
What structural features are associated with the subtypes of muscarinic AChRs
M1- Gq M2- Gi M3- Gq M4-Gi M5- Gq
Where are the nicotinic receptors found?
Nm - skeletal muscle, neuromuscular junction
Nn- Postganglionic cell body, dendrites, CNS
Nicotinic receptor mechanism
sodium, potassium depolarizing ion channel
direct vs indirect cholinergic agonists
Direct-acting
Limited use due to poor absorption and distribution
Some are also rapidly hydrolyzed by AChE
Indirect-acting
Acetylcholinesterase (AChE) inhibitors
Utility determined by pharmacokinetics
Types of cholinergic antagonists
Antinicotinic Agents
Neuromuscular Blockers
Ganglion Blockers
Antimuscarinic Agents
Prototype: atropine
Many other compounds; utility determined by pharmacokinetics and receptor selectivity
Cholinergic Agonists
Mimic the actions of ACh on nAChRs and mAChRs
Classified based on their mechanism of action
choline esthers, alkaloids
Actions: pupillary constriction, near vision, salivation, bronchial constriction and secretion, slowed heart rate, gastric secretion, diarrhea, voiding of urine
SLUDGE- salivation, lacrimation, urination, defecation, GI, emesis
Choline Esters and examples
MOA: agonists at cholinergic receptors Permanently charged (poor absorption and distribution)
Quaternary amines
Acetylcholine- susceptible to cholinesterse
Methacholine- somewhat suceptible to cholinesterase
Carbachol
Bethanechol
Cholinomimetic Alkaloids
MOA: agonists at cholinergic receptors
Uncharged tertiary amines that are well absorbed (e.g., nicotine patch)
Muscarine is charged but can cross the BBB and is highly toxic when ingested (e.g., mushrooms)
Pilocarpine (used for xerostomia)- think of eating a pile of carp and getting so thirsty
Nicotine
Lobeline
Major Clinical Uses of Direct-Acting Cholinergic Agonists
Diseases of the eye,
GI/ GU disorders
Muscarinic agonists in the eye
Iris sphincter and ciliary muscle contraction cause increased aqueous humor outflow into the canal of Schlemm (drains the anterior chamber)
Clinical relevance:
- Glaucoma (replaced by β-blockers, prostaglandins)
- Accommodative esotropia: misalignment of the eyes caused by hypermetropic accommodative error (farsightedness)
Muscarinic agonists in GI/ GU smooth muscle
M3 activation is excitatory (signaling pathway)
M2 activation is inhibitory (signaling pathway)
BOTH cause smooth muscle contraction
Functional effects:
Increased motility and tone
Increased secretions from salivary and gastric glands»_space; pancreas and small intestinal glands
Clinical relevance Postoperative ileus Congenital megacolon Esophageal reflux Neurogenic bladder Xerostomia (Sjögren’s syndrome)
Direct-Acting Cholinergic Agonists and their uses
- Acetylcholine
Approved for intraocular use during surgery and causes miosis (reduction in pupil size) - Bethanechol
Selective mAChR agonist that primarily affects the urinary and GU tracts
Can be used to treat patients with neurogenic bladder and urinary retention
Little cardiovascular stimulation
May produce urinary tract infection if sphincter fails to relax - Carbachol
Nonspecific cholinergic agonist that is used for the treatment of glaucoma or to produce miosis during surgery or ophthalmic examination - Methacholine
Selective and potent mAChR agonist used in diagnosis of bronchial airway hyperreactivity - Pilocarpine
Approved for xerostomia (Sjögren’s syndrome or head and neck cancer treatment related), miosis during ophthalmic procedures (topical), and for glaucoma (topical)
Pure mAChR agonist
Cevimeline
Synthetic muscarinic agonist
Selective for M3 receptors
Oral tablet used to treat dry mouth (xerostomia) in patients with Sjögren’s syndrome
Common AEs include excessive sweating, nausea, blurred vision
Varenicline (Chantix)
FDA approved for smoking cessation
Partial agonist that binds with high affinity and selectivity to α4β2 nAChRs (NN)
MOA: stimulation and subsequent moderate, sustained release of mesolimbic dopamine are thought to reduce craving and withdrawal symptoms associated with smoking cessation
Adverse effects: nausea and insomnia
Serious AEs (warrants discontinuation): neuropsychiatric symptoms, including changes in behavior, agitation, depressed mood, suicidal ideation, and attempted and completed suicide
Toxicity of Direct-Acting Cholinergic Agonists: Muscarinic stimulants
Muscarinic stimulants
Nausea, vomiting, diarrhea, urinary urgency, salivation, sweating, cutaneous vasodilation, bronchial constriction/wheezing, increase in glandular secretion (SLUDGE)
Contraindicated in patients who have asthma, hyperthyroidism, coronary insufficiency, acid-peptic disease
Treatment
Antimuscarinic (atropine